Manzo Pharmaceuticals, Inc.
OTC: MNZO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Financial Services
- Industry
- Shell Companies
- CEO
- Kenneth Manzo
- Employees
- 12
- Headquarters
- Milford, United States
- IPO year
- 1998
- Market cap
- $116.0K
- Website
- https://www.lactofreedom.com
Loading MNZO…
Loading profile data…Frequently asked questions about MNZO
What does Manzo Pharmaceuticals, Inc. (MNZO) do?
Manzo Pharmaceuticals, Inc. is a specialized drug company that focuses on the discovery, creation, and evaluation of both proprietary and generic medical treatments and therapies. The company is actively developing Lacto-Freedom, a patented probiotic designed to help individuals with lactose intolerance digest dairy-containing foods more easily....
Where does MNZO trade?
Manzo Pharmaceuticals, Inc. (MNZO) trades on the Other OTC.
What sector is MNZO in?
Manzo Pharmaceuticals, Inc. (MNZO) operates in the Financial Services sector, specifically in the Shell Companies industry.
Who is the CEO of Manzo Pharmaceuticals, Inc.?
Kenneth Manzo is the chief executive officer of Manzo Pharmaceuticals, Inc. (MNZO).
Where is Manzo Pharmaceuticals, Inc. headquartered?
Manzo Pharmaceuticals, Inc. is headquartered in United States.
Does MNZO pay a dividend?
Manzo Pharmaceuticals, Inc. (MNZO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MNZO go public?
Manzo Pharmaceuticals, Inc. (MNZO) completed its initial public offering in 1998.